A review of techniques oncology nurses can use to help themselves cope with their feelings as they navigate through the effects of the COVID-19 pandemic on their practice, their patients, and themselves.
The FDA previously granted Fast Track and Orphan Drug designations to mepolizumab for the treatment of HES.
It may be important to sequence
ETV6in patients with inherited thrombocytopenia or malignancy and to schedule regular follow-ups to check for secondary cancers.
Emapalumab as a target therapy may benefit children with primary HLH.
In this phase I clinical trial, 2 different cohorts of patients with acute GVHD received subcutaneous injections of uhCG along with standard-of-care treatment.
Families affected by the emotional burden of childhood cancer often face significant financial difficulty due treatment expenses and time away from work.
Although pediatric patients with malignancy-associated HLH may have low mortality rates, they may subsequently die from underlying conditions from the malignant disease.
After defining mortality-related parameters in HLH, investigators noted that mortality rates were still high for patients with primary immunodeficiency.
Cancer is among the underlying conditions that increase risk for COVID-19.
Researchers assessed data from patients with CAD with the aim of providing information on real-world, long-term outcomes of previously studied therapies.
Investigators aimed to characterize HLH in patients with moderate-to-severe inflammatory bowel disease.
The FDA has approved a phase 1/2a study evaluating the use of umbilical cord mesenchymal stem cells for the treatment of patients with severe cases of COVID-19.
The use of soluble interleukin-2 receptor level as a diagnostic test for secondary HLH in adults may be flawed.
An international registry dedicated to pediatric patients with cancer infected with COVID-19 was made possible through an international collaboration.
ILROG has issued guidelines on alternative radiation treatment methods to combat limited treatment resources for cancer patients during the COVID-19 pandemic.
This study focused on a cohort of nonelderly Medicaid beneficiaries with stage IV breast or colorectal cancer who resided in New Jersey.
Sustained improvement was noted after the administration of tocilizumab, an interleukin-6 antagonist.
Investigators recommend that clinicians monitor WBC, lymphocyte, and platelet counts, as well as IL-6 and serum ferritin, in hospitalized COVID-19 patients with respiratory distress.
Inclusion of nurses in the development of health care programs relating to prevention and management of COVID-19 infection was a key element of the ISNCC position statement.
Splenectomy may be a safe therapeutic options for children with nonmalignant hematologic diseases who have proper vaccinations and follow-up care.
The FDA has approved the supplemental Biologics License Application (sBLA) for Keytruda® (Merck) to include an additional recommended dosage of 400mg every 6 weeks across all adult indications.
Burnout rates among pediatric hematology/oncology fellows may be influenced by less patient-centered care and less humanistic practice.
The use of telemedicine has been surging since the onset of COVID-19, with millions of Americans now using this medium for connecting with their clinicians.
Oncologists should consistently encourage and support children undergoing acute cancer treatments to continue to be physically active.
Fedratinib, a selective inhibitor of JAK2, was approved in 2019 by the US FDA for the treatment of certain groups of patients with myelofibrosis.
Pyruvate kinase deficiency in erythrocytes can lead to hemolysis, which may cause significant hematologic comorbidities such as anemia, thrombosis, and iron overload.
A study has shown that female cancer survivors may have a higher risk of cardiac events with some antihypertensive medications.
Neither transcriptional nor proteomic profiling revealed significant differences between F- and A-cells at baseline or after HbF-inducing treatment.
The ASCO document focused on the development of policies for allocating health care resources that also specifically address oncology.
Patients with cancer enrolled in clinical trials during the COVID-19 pandemic represent a particularly vulnerable patient population.
Genotypic assessment of maternal plasma via ddPCR is a safe and reliable method to determine fetal HPA non-invasively.
The FDA has launched a new webpage with information for recovered individuals who were infected with coronavirus disease 2019 (COVID-19) on where they can go to donate plasma to aid in the treatment of severely ill patients.
Risk of immunosuppression and risk of exposure at health care facilities have tipped the pendulum of the risk-benefit ratio.
An expert panel of clinicians developed guidelines for the use of rituximab in the maintenance of remission for adult ANCA-associated vasculitis.
Most cancer care is delivered at community oncology centers, but research regarding the barriers to clinical trial enrollment in this setting has been limited.
Study will enroll approximately 270 adult patients globally.
Although allogeneic HCT is associated with increased risk for keratinocyte carcinoma, the magnitude of risk linked to certain patient characteristics is still unknown.
Hydroxychloroquine is a less-toxic metabolite of the antimalarial drug chloroquine and is used as an immunomodulator for the treatment of autoimmune diseases.
Patient interviews revealed that most readmissions occur because patients are unsure of the availability and suitability of their care resources at home and in the outpatient setting.
The American Board of Internal Medicine (ABIM) announced that certified physicians who have a Maintenance of Certification (MOC) requirement due in 2020 will now have until the end of 2021 to complete it.
Patients with severe pneumonia due to SARS-CoV-2 infection who have high D-dimer levels may benefit from anticoagulation therapy.
Survivors of childhood hematologic malignancies with poorly reported patient outcomes may have more chronic health conditions, regardless of treatment method.
Recommendations issued apply to patients and those providing patient care.
A substantial proportion of US medical education program directors reported considering resignation at some point in their careers.
There was evidence that sensitivity may be low in early stage disease (18% for stage I in all cancer types), vs 43%, 81%, and 93% in stages II, III, and IV, respectively.
The aim of this qualitative study was to explore the perspectives of clinical trial “stakeholders” regarding enrollment of minorities in cancer clinical trials.
For patients with porphyria cutanea tarda, reduced health-related quality of life may be associated with lack of treatment initiation and more symptoms.
The Agency believes that the ability to manage the cytokine storm associated with COVID-19 may decrease patient morbidity.
Patients with cancer aged 65 and older are likely to be taking 5 or more medications before treatment with IV chemotherapy, which can complicate posttreatment care.
While 85% of nonatopic donors matched with nonatopic recipients remained nonatopic, 61% of atopic donors matched with atopic recipients became nonatopic after AHCT.
Transgender patients present unique communication as well as clinical challenges for oncology clinicians.